Clinical trials: Pyoderma Gangrenosum, active
Pyoderma Gangrenosum
A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma Gangrenosum
This study was designed to assess the therapeutic efficacy and safety of SHR-1139 Injection in adult patients with ulcerative pyoderma gangrenosum.
- Trial name
- NCT07337564
- Testing
- SHR-1139 Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shandong First Medical University
Diabetic Foot, Pressure Ulcer
A Real-World Registry of Chronic Wounds and Ulcers
WOUNDJOURNEY is a longitudinal, real-world, observational registry designed to capture the full clinical course and patient journey associated with chronic wounds and ulcers.
- Conditions
- Diabetic Foot, Pressure Ulcer, Surgical Wound Dehiscence, Vasculitis
- Trial name
- WOUNDJOURNEY (NCT02280733)
- Testing
- Usual care
- Where
- United States
- Volunteers
- 300,000 people
- Sponsor
- U.S. Wound Registry
Pyoderma Gangrenosum
A Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum
This study aims to evaluate the efficacy, safety, pharmacokinetics (PK) and immunogenicity of SHR-1139 Injection in patients with pyoderma gangrenosum.
- Trial name
- NCT07444684
- Testing
- SHR-1139 Injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Pyoderma Gangrenosum
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
The purpose of this study is to find out whether a medicine called spesolimab helps people with pyoderma gangrenosum (PG). The main aim is to see whether spesolimab leads to closure of PG ulcers.
- Trial name
- NCT06624670
- Testing
- Spesolimab, Prednisone, Prednisolone
- Where
- 104 sites in United States, Argentina and 19 more
- Volunteers
- 90 people
- Sponsor
- LEO Pharma
Pyoderma Gangrenosum
Efficacy of Bimekizumab in Adults With Pyoderma Gangrenosum
The purpose of the study is to learn more about an experimental drug bimekizumab that may be helpful for Pyoderma Gangrenosum (PG). Bimekizumab will be referred to as the study drug throughout this form.
- Trial name
- BEAT-PG (NCT07767864)
- Testing
- Bimekizumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Oregon Health and Science University
Pyoderma Gangrenosum, Skin Diseases
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
A single-arm open-label study assessing short-term (week 6, 16) and long-term (week 32) efficacy of guselkumab in adult participants with pyoderma gangrenosum (PG)
- Conditions
- Pyoderma Gangrenosum, Skin Diseases, Wound Heal, Pyoderma
- Trial name
- GEORGE (NCT06563323)
- Testing
- Guselkumab
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Oregon Health and Science University
Post-COVID-19 Condition, Ulcerative Colitis
Emerging Indications for Hyperbaric Oxygen Treatment
This study will evaluate the effectiveness of hyperbaric oxygen therapy (HBOT) on treating emerging indications (i.e., conditions that have shown to potentially benefit from HBOT) using the Multicenter Registry for Hyperbaric…
- Conditions
- Post-COVID-19 Condition, Ulcerative Colitis, Crohn Disease, Calciphylaxis
- Trial name
- NCT07240649
- Testing
- Hyperbaric oxygen treatment (HBOT), 100% Oxygen
- Volunteers
- 100 people
- Sponsor
- Jay C. Buckey Jr.
Pyoderma Gangrenosum
Topical Ruxolitinib in the Treatment of Adults With Pyoderma Gangrenosum
This is a single-center, open-label, single-arm pilot study evaluating topical ruxolitinib (OPZELURA) as a treatment for adults with Pyoderma Gangrenosum (PG), a chronic inflammatory skin condition that causes painful ulcers.
- Trial name
- TRIUMPH (NCT07783412)
- Testing
- topical ruxolitinib 1.5% cream
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Oregon Health and Science University